Sc Pharmaceuticals's - SCPH market analysis on 27th September 2020

Transaction Date	Recipient	Shares	Type	Price	Value
21st September 2020	Advisors Llc Orbimed	137,500	Open or private sale	$28.00	$3,850,000.00
21st September 2020	Capital Management, L.P. Ra	2,145,045	Conversion of derivative	$0.00
21st September 2020	Capital Management, L.P. Ra	660,000	Open or private purchase	$19.00	$12,540,000.00
17th September 2020	Capital Management, L.P. Ra	1,300,000	Open or private purchase	$28.00	$36,400,000.00
15th September 2020	Advisors Llc Orbimed	902,885	Grant/award etc.	$0.00
15th September 2020	Advisors Llc Orbimed	4,822,960	Grant/award etc.	$0.00
15th September 2020	Advisors Llc Orbimed	292,607	Grant/award etc.	$0.00
9th September 2020	Capital Management, L.P. Ra	158,589	Open or private sale	$25.81	$4,092,738.04
21st August 2020	Capital Management, L.P. Ra	2,129,003	Conversion of derivative	$0.00
18th August 2020	Advisors Llc Orbimed	43,543	Open or private sale	$108.54	$4,726,157.22

Sc Pharmaceuticals

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

scPharmaceuticals, Inc. was founded by Pieter Muntendam and Bertram Pitt in February 2013. Its products include furosemide, used as parenteral diuretic in treating heart failure.

Ticker: SCPH

Sector: Health Technology

Industry: Pharmaceuticals: Major

SEC Central Index Key (CIK): 1604950

Employees: 17

Exchange: NASDAQ

Auditor Opinion:

You must Login to see Language Changes

Disclosure Language changes

Analysis of subtle changes in disclosure language. Red is a sign of more constrained, less positive language changes etc. Green is more positive, less constrained etc.

You must Login to see analysis